We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

76 hedge funds and large institutions have $342M invested in Taro Pharmaceutical Industries Ltd. in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

4% less capital invested

Capital invested by funds: $357M → $342M (-$15.6M)

5% less funds holding

Funds holding: 8076 (-4)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

39% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 31

Holders
76
Holders Change
-4
Holders Change %
-5%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
7
Increased
19
Reduced
31
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$53.1M -$1.15M -15,700 -2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$39.1M -$5.88M -79,982 -13%
KAM
3
Krensavage Asset Management
New York
$39.1M -$289K -3,934 -0.7%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$37.6M +$1.44M +19,547 +4%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$25M -$273K -3,715 -1%
BIP
6
Brandes Investment Partners
California
$18.3M -$11.1M -151,114 -37%
Ameriprise
7
Ameriprise
Minnesota
$13.2M +$7.34M +99,945 +119%
Invesco
8
Invesco
Georgia
$12.9M +$1.27M +17,279 +11%
EP
9
Eversept Partners
New York
$12.5M +$725K +9,871 +6%
BlackRock
10
BlackRock
New York
$12.1M -$1.3M -17,705 -10%
Hotchkis & Wiley Capital Management
11
Hotchkis & Wiley Capital Management
California
$9.2M +$1.35M +18,340 +17%
M
12
Murchinson
Ontario, Canada
$7.2M +$7.35M +100,000 New
Northern Trust
13
Northern Trust
Illinois
$6.74M -$371K -5,046 -5%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$6.6M -$499K -6,788 -7%
AIM
15
ARK Investment Management
Florida
$5.51M -$149K -2,029 -3%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$4.49M -$328K -4,471 -7%
Norges Bank
17
Norges Bank
Norway
$4.37M -$1.03M -14,000 -19%
PPA
18
Parametric Portfolio Associates
Washington
$4.36M +$933K +12,700 +27%
N
19
Nuveen
North Carolina
$4.14M +$222K +3,024 +6%
State Street
20
State Street
Massachusetts
$3.58M +$32.9K +448 +0.9%
Morgan Stanley
21
Morgan Stanley
New York
$3.53M +$2.5M +33,979 +226%
JP Morgan Chase
22
JP Morgan Chase
New York
$2.2M -$239K -3,248 -10%
AIIMS
23
Analyst IMS Investment Management Services
Israel
$1.64M
Swiss National Bank
24
Swiss National Bank
Switzerland
$1.53M -$44.1K -600 -3%
Goldman Sachs
25
Goldman Sachs
New York
$1.1M -$169K -2,294 -13%

TARO Hedge Fund Activity: Q2 2021 in Review

76 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2021, worth a combined $342M — down 4.4% from $357M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TARO and 7 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 19 added.

The largest buyer was Ameriprise, adding an estimated $7.34M. The largest seller was Brandes Investment Partners, cutting an estimated $11.1M.

  • 76 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2021, down from 80 in Q1 2021.
  • Funds reported $342M of Taro Pharmaceutical Industries Ltd. stock for Q2 2021, down 4.4% quarter-over-quarter.
  • 7 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2021 and 11 closed out, a net change of -4 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2021 was Ameriprise, an estimated $7.34M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2021 was Brandes Investment Partners, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2021.